Mumps and Male Fertility: Orchitis Risk, Sterility Rates, and Vaccination
Mumps Orchitis
- Occurs in 15–30% of post-pubertal males with mumps (rare in prepubertal).
- Usually unilateral (70–90%); bilateral in 10–30%.
- Onset: 4–8 days after parotitis; may precede or occur without parotitis.
Sterility Risk
- Testicular atrophy: 30–50% of affected testes.
- Clinical sterility (azoospermia): Rare—estimated <1% of all mumps cases; ~10–15% of bilateral orchitis cases.
- Subfertility (reduced count/motility): More common, often transient.
Mechanism
Viral invasion → seminiferous tubule inflammation, edema, pressure necrosis → fibrosis. Leydig cells (testosterone) usually spared.
Prevention
- MMR vaccine: 2 doses (12–15 mo, 4–6 yr); 88% effective against mumps.
- Outbreak settings: Third dose recommended for at-risk groups.
- Post-exposure: Vaccine not effective; immune globulin not indicated.
Management
- Supportive: Scrotal support, NSAIDs, cold packs, bed rest.
- Corticosteroids: Not routinely recommended; limited evidence.
- Semen analysis: At 3–6 months post-recovery if fertility concern.
Vaccination is the most effective strategy to prevent mumps and its reproductive complications.
Pregnancy & Health - Related Articles
- False Negative Pregnancy Test Despite Period-Like Bleeding
- Pre-Pregnancy Checklist: Optimize Health for a Healthy Pregnancy
- Calculating Conception Date from Due Date: A Simple Guide
- Rising Multiple Births: Fertility Treatments, Maternal Age, and Other Drivers
- Cymbalta (Duloxetine) Does Not Interfere with Pregnancy Test Accuracy
- Early Pregnancy Testing: When Can You Test Before a Missed Period?
- Smoking During Pregnancy: Health Risks for Mother and Baby
